留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

MELD评价体系对肝移植受者选择的多中心临床研究进展

周林 潘立超 史宪杰 杜国盛

周林, 潘立超, 史宪杰, 等. MELD评价体系对肝移植受者选择的多中心临床研究进展[J]. 器官移植, 2017, 8(2): 174-178. doi: 10.3969/j.issn.1674-7445.2017.02.016
引用本文: 周林, 潘立超, 史宪杰, 等. MELD评价体系对肝移植受者选择的多中心临床研究进展[J]. 器官移植, 2017, 8(2): 174-178. doi: 10.3969/j.issn.1674-7445.2017.02.016

MELD评价体系对肝移植受者选择的多中心临床研究进展

doi: 10.3969/j.issn.1674-7445.2017.02.016
基金项目: 

军队十二五课题面上项目 CWS11J096

国家自然科学基金 81370578

详细信息
    通讯作者:

    史宪杰,Email:shixianjie301@126.com

  • 中图分类号: R617

  • 摘要: 供肝短缺是目前肝移植所面临的全球性问题,高效地分配和利用日益短缺的供肝资源,让更多的患者获益,显得尤为重要。然而,如何评判等待名单的患者是否为合适移植受者,需要严格的评价标准。相比Child-Pugh评分而言,终末期肝病模型(MELD)克服了临床医师和量化指标参数的主观性、缺乏衡量标准化统一等缺点,以客观的实验室指标作为评价标准,可公正、客观、精准地反映肝硬化患者的短期存活率和死亡风险。作为一种较理想的评价模型,基本完全达到“最危急、最需者优先”的临床目的。笔者对2002年美国器官资源共享网络(UNOS)采用MELD评分模型以来的多中心临床经验进行总结分析,旨在综合评价MELD的临床实用性、有效性及存在的问题,为临床肝移植评价受者提供指导。

     

  • [1] Asrani SK. Liver transplantation for nonalcoholic steato-hepatitis[J]. Clin Gastroenterol Hepatol, 2014, 12(3):403-404. DOI: 10.1016/j.cgh.2013.11.014.
    [2] Asrani SK, Kamath PS. Model for end-stage liver disease score and MELD exceptions: 15 years later[J]. Hepatol Int, 2015, 9(3):346-354. DOI: 10.1007/s12072-015-9631-3.
    [3] Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK[J]. Gut, 2008, 57(2):252-257. doi: 10.1136/gut.2007.131730
    [4] Dabbous H, Sakr M, Abdelhakam S. Living donor liver transplantation for high model for end-stage liver disease score: what have we learned?[J]. World J Hepatol, 2016, 8(22):942-948. DOI: 10.4254/wjh.v8.i22.942.
    [5] Schlegel A, Linecker M, Kron P, et al. Risk assessment in high and low MELD liver transplantation[J]. Am J Transplant, 2016, DOI: 10.1111/ajt.14065.[Epub ahead of print].
    [6] Suzuki H, Bartlett AS, Muiesan P, et al. High model for end-stage liver disease score as a predictor of survival during long-term follow-up after liver transplantation[J]. Transplant Proc, 2012, 44 (2):384-388. DOI: 10.1016/j.transproceed.2011.11.013.
    [7] Sotiropoulos GC, Vernadakis S, Paul A, et al. Single-center experience on liver transplantation for model for end-stage liver disease score 40 patients[J]. Dig Dis Sci, 2016, 61(11):3346-3353. doi: 10.1007/s10620-016-4274-3
    [8] Rostved AA, Lundgren JD, Hillings∅ J, et al. MELD score measured day10 after orthotopic liver transplantation predicts death and re-transplantation within the first year[J]. Scand J Gastroenterol, 2016, 51(11):1360-1366. DOI: 10.1080/00365521.2016.1196497.
    [9] Massie AB, Chow EK, Wickliffe CE, et al. Early changes in liver distribution following implementation of share 35[J]. Am J Transplant, 2015, 15(3):659-667. DOI: 10.1111/ajt.13099.
    [10] Chow EK, Massie AB, Luo X, et al. Waitlist outcomes of liver transplant candidates who were reprioritized under share 35[J]. Am J Transplant, 2016, DOI: 10.1111/ajt.13980.[Epub ahead of print].
    [11] Washburn K, Harper A, Baker T, et al. Changes in liver acceptance patterns after implementation of share 35[J]. Liver Transpl, 2016, 22(2): 171-177. DOI: 10.1002/lt.24348.
    [12] Feng S, O'Grady J. Share 35: a liver in time saves lives?[J]. Am J Transplant, 2015, 15(3): 581-582. DOI: 10.1111/ajt.13102.
    [13] Hamaguchi Y, Kaido T, Okumura S, et al. Proposal of muscle-MELD score, including muscularity, for prediction of mortality after living donor liver transplantation[J]. Transplantation, 2016[Epub ahead of print]. https://www.researchgate.net/profile/Ahmed_Hammad16/publication/306026646_Proposal_of_Muscle-MELD_score_including_muscularity_for_prediction_of_mortality_after_living_donor_liver_transplantation/links/57c3bdfd08aed246b102ab42.pdf?origin=publication_detail
    [14] Myers RP, Shaheen AA, Aspinall AI, et al. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate[J]. J Hepatol, 2011, 54(3):462-470. DOI: 10.1016/j.jhep.2010.07.015.
    [15] Lai JC, Terrault NA, Vittinghoff E, et al. Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system[J]. Am J Transplant, 2010, 10(12):2658-2664. DOI: 10.1111/j.1600-6143.2010.03326.x.
    [16] Bloom RD, Bleicher M. Simultaneous liver-kidney transplantation in the MELD era[J]. Adv Chronic Kidney Dis, 2009, 16(4):268-277. DOI: 10.1053/j.ackd.2009.05.005.
    [17] Mariante-Neto G, Marroni CP, Fleck Junior AM, et al. Impact of creatinine values on MELD scores in male and female candidates for liver transplantation[J]. Ann Hepatol, 2013, 12(3):434-439. https://www.researchgate.net/publication/236338396_Impact_of_creatinine_values_on_MELD_scores_in_male_and_female_candidates_for_liver_transplantation
    [18] Annunziata TB, Paulino K, Fernandes R, et al. Impact of model for end-stage liver disease score in post-liver transplantation prognosis[J]. Transplant Proc, 2016, 48(7):2348-2351. DOI: 10.1016/j.transproceed.2016.08.003.
    [19] Foxton MR, Al-Freah MA, Portal AJ, et al. Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs[J]. Liver Transpl, 2010, 16(5):668-677. DOI: 10.1002/lt.22027.
    [20] Weismuller TJ, Fikatas P, Schmidt J, et al. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany-limitations of the 'sickest first'-concept[J]. Transpl Int, 2011, 24(1):91-99. DOI: 10.1111/j.1432-2277.2010.01161.x.
    [21] Uehlinger NB, Beyeler F, Weiss J, et al. Organ transplantationin Switzerland: impact of the new transplant law on cold ischaemia time and organ transports[J]. Swiss Med Wkly, 2010, 140(15/16):222-227. DOI: smw-12965.
    [22] Jurado-García, Muñoz García-Borruel M, Rodríguez-Perálvarez ML, et al. Impact of MELD allocation system on waiting list and early post-liver transplant mortality[J]. PLoS One, 2016, 11(6):e0155822. DOI: 10.1371/journal.pone.0155822.
    [23] Elwir S, Lake J.Current status of liver allocation in the United States[J]. Gastroenterol Hepatol, 2016, 12(3):166-170. https://experts.umn.edu/en/publications/current-status-of-liver-allocation-in-the-united-states
    [24] Castro RS, Deisanti D, Seva-Pereira T, et al. Survival before and after model for end-stage liver disease score introduction on the Brazilian liver transplant waiting list[J]. Transplant Proc, 2010, 42(2):412-416. DOI: 10.1016/j.transproceed.2010.01.028.
    [25] McCormack L, Gadano A, Lendoire J, et al. Model for end-stage liver disease based allocation system for liver transplantation in Argentina: does it workoutside the United States?[J]. HPB, 2010, 12(7):456-464. DOI: 10.1111/j.1477-2574.2010.00199.x.
    [26] Kalra A, Wedd JP, Biggins SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more[J]. Curr Opin Organ Transplant, 2016, 21(2):120-126. DOI: 10.1097/MOT.0000000000000281.
    [27] Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States[J]. JAMA Surg, 2015, 150(3):252-259. DOI: 10.1001/jamasurg.2014.2038.
    [28] Piscaglia F, Cucchetti A, Bolondi L. "Survival benefit": the final destination, with still a long way to go[J]. Dig Liver Dis, 2010, 42(9):608-610. DOI: 10.1016/j.dld.2010.07.001.
    [29] Freeman RB, Gish RG, Harper A, et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula[J]. Liver Transpl, 2006, 12(12 Suppl 3):S128-S136. https://www.researchgate.net/publication/51374420_Model_for_End-Stage_Liver_Disease_MELD_exception_guidelines_Results_and_recommendations_from_the_MELD_exception_study_group_and_conference_MESSAGE_for_the_approval_of_patients_who_need_liver_transplan
    [30] Bahra M, Neuhaus P. Liver transplantation in the high MELD era: a fair chance for everyone?[J]. Langenbecks Arch Surg, 2011, 396(4):461-465. DOI: 10.1007/s00423-011-0766-y.
    [31] Ushigome H, Nakao T, Harada S, et al. Elderly living donor liver transplant recipients over 60 years old at a Japanese single center[J]. Transplant Proc, 2016, 48(4):1115-1118. DOI: 10.1016/j.transproceed.2015.12.103.
    [32] Viganò L, Laurent A, Tayar C, et al. Outcomes in adult recipients of right-sided liver grafts in split-liver procedures[J]. HPB, 2010, 12(3):195-203. DOI: 10.1111/j.1477-2574.2009.00147.x.
    [33] Park CW, Tsai NT, Wong LL. Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more[J]. Clin Transplant, 2011, 25(6):E606-E611. DOI: 10.1111/j.1399-0012.2011.01497.x.
    [34] Massie AB, Caffo B, Gentry SE, et al. MELD exceptions and rates of waiting list outcomes[J]. Am J Transplant, 2011, 11(11):2362-2371. DOI: 10.1111/j.1600-6143.2011.03735.x.
    [35] Cucchetti A, Cescon M, Bertuzzo V, et al. Can the dropout risk of candidates with hepatocellular carcinoma predict survival after liver transplantation?[J]. Am J Transplant, 2011, 11(8):1696-1704. DOI: 10.1111/j.1600-6143.2011.03570.x.
    [36] Toso C, Dupuis-Lozeron E, Majno P, et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list[J]. Hepatology, 2012, 56(1): 149-156. DOI: 10.1002/hep.25603.
    [37] Washburn K, Edwards E, Harper A, et al. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system[J]. Am J Transplant, 2010, 10(7):1643-1648. DOI: 10.1111/j.1600-6143.2010.03127.x.
    [38] TandoiF, Ponte E, Saffioti MC, et al. Liver transplantation for hepatocellular carcinoma within Milan criteria in patients with model for end-stage liver disease score below 15: the impact of the etiology of cirrhosis on long-term survival[J]. Transplant Proc, 2013, 45(7):2711-2714. DOI: 10.1016/j.transproceed.2013.07.002.
    [39] Roma J, Balbi E, Pacheco-Moreira L, et al. Impact of model for end-stage liver disease score on long-term survival following liver transplantation for hepatocellular carcinoma[J]. Transplant Proc, 2012, 44(8):2423-2427. DOI: 10.1016/j.transproceed.2012.07.026.
    [40] Alver SK, Lorenz DJ, Marvin MR, et al. Projected outcomes of 6-month delay in exception points vs. an equivalent MELD score for HCC liver transplant candidates[J]. Liver Transpl, 2016, 22(10):1343-155. DOI: 10.1002/lt.24503.
  • 加载中
计量
  • 文章访问数:  175
  • HTML全文浏览量:  72
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-11-20
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2017-03-15

目录

    /

    返回文章
    返回